Format

Send to

Choose Destination
J Am Coll Cardiol. 2016 Jun 21;67(24):2888-99. doi: 10.1016/j.jacc.2016.02.082.

Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.

Author information

1
Fresenius Medical Care North America, Waltham, Massachusetts; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: kevin.chan@fmc-na.com.
2
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
3
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
4
Maine Medical Center, Tufts University School of Medicine, Portland, Maine.
5
George Institute for Global Health, University of Sydney, Sydney, Australia.
6
Fresenius Medical Care North America, Waltham, Massachusetts.
7
Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.

Erratum in

Abstract

Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance <25 ml/min were excluded from all the pivotal phase 3 NOAC trials. It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease (creatinine clearance <30 ml/min) and those on dialysis. The authors frame the evidence in terms of risk versus benefit to bring greater clarity to NOAC-related major bleeding and efficacy at preventing stroke specifically in patients with creatinine clearance <30 ml/min.

KEYWORDS:

apixaban; dabigatran; edoxaban; renal dialysis; rivaroxaban; stroke

PMID:
27311528
DOI:
10.1016/j.jacc.2016.02.082
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center